Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Oxford Biomedica plc. (12/22/22). "Press Release: Oxford Biomedica to Present at 41st Annual J.P. Morgan Healthcare Conference". Seattle, WA.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Oxford Biomedica plc (LSE: OXB)
  Group Oxford Biomedica (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
  Product 2 lentiviral vector
Index term Index term Oxford Biomedica–JPMorgan Chase: investor conference, 202301 supply service Oxford Biomedica presents at JP Morgan Healthcare Conference 2023
Persons Person Paynter, Stuart (Oxford BioMedica 201708– CFO before De La Rue plc + Shire Pharmaceuticals + Steris)
  Person 2 Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)
     


Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, 11 January 2023 at 4.30pm PT. The presentation will be available on the Oxford Biomedica website after the conference at www.oxb.com/investors/results-reports-presentations-webcasts.


-Ends-


Enquiries:

Oxford Biomedica plc:
Stuart Paynter, Chief Financial Officer – T: +44 (0)1865 783 000
Taylor Boyd, VP, Head of IR – T: +1 919 539 1234
Sophia Bolhassan, VP, Head of Corporate Affairs – T: +44 (0)7394 562 425

Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Cole / Angela Gray


About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.

   
Record changed: 2023-06-05

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x200px

More documents for Oxford Biomedica (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x300px




» top